# Genotyping Guided Individualized Treatment of Clopidogrel and Ticagrelor in ACS

> **NCT02048228** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 200 (estimated)

## Conditions studied

- CLOPIDOGREL, POOR METABOLISM of (Disorder)

## Interventions

- **DRUG:** genotyping guided therapy Ticagrelor, Clopidogrel
- **DRUG:** standard therapy clopidogrel

## Key facts

- **NCT ID:** NCT02048228
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-10
- **Primary completion:** 2016-03
- **Final completion:** 2016-08
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2014-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02048228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02048228, "Genotyping Guided Individualized Treatment of Clopidogrel and Ticagrelor in ACS". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02048228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*